Meal Replacements in the Treatment of Adolescent Obesity: A Randomized Controlled Trial
| Autor: | Melissa S. Xanthopoulos, Thomas A. Wadden, Chanelle T. Bishop-Gilyard, Natalie L. Trumpikas, Joanna L. Cronquist, Lorraine E. Levitt Katz, Reneé H. Moore, Leslie G. Womble, Christine A. Gehrman, Robert I. Berkowitz |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Patient Dropouts Time Factors Adolescent Diet Reducing Endocrinology Diabetes and Metabolism Medicine (miscellaneous) Overweight Weight Gain Gastroenterology Article Body Mass Index law.invention Endocrinology Randomized controlled trial Behavior Therapy Weight loss law Internal medicine Weight Loss Secondary Prevention medicine Humans Single-Blind Method Obesity Life Style Food Formulated Meal Nutrition and Dietetics Random assignment business.industry medicine.disease Surgery Adolescent Behavior Female medicine.symptom business Weight gain Body mass index Follow-Up Studies |
| Zdroj: | Obesity. 19:1193-1199 |
| ISSN: | 1930-7381 |
| DOI: | 10.1038/oby.2010.288 |
| Popis: | Use of meal replacements (MRs) in lifestyle modification programs (LMPs) for obese adults significantly increases weight loss, compared with prescription of an isocaloric conventional diet (CD). This 12-month randomized trial examined 113 obese adolescents (mean ± s.d. age of 15.0 ± 1.3 years and BMI of 37.1 ± 5.1 kg/m2) who were assigned to a LMP, combined with meal plans of 1,300–1,500 kcal/day of CD (self-selected foods) or MR (three SlimFast shakes, one prepackaged meal, five vegetable/fruit servings). After month 4 (phase 1), participants originally treated with MR were unmasked to their phase 2 (months 5–12) random assignment: continued use of MR (i.e., MR+MR) or transitioned to CD (i.e., MR+CD). Participants initially treated with CD in phase 1, continued with CD (i.e., CD). All three groups were treated for an additional 8 months (phase 2). Regression models were used to evaluate percentage change in BMI from baseline to month 4 (phase 1), months 5–12 (phase 2), and baseline to month 12. At month 4, participants assigned to MR (N = 65) achieved a mean (±s.e.) 6.3 ± 0.6% reduction in BMI, compared to a significantly (P = 0.01) smaller 3.8 ± 0.8% for CD participants (N = 37). In phase 2, BMI increased significantly (P < 0.001) in all three conditions, resulting in no significant (P = 0.39) differences between groups in percentage change in BMI at month 12. Across groups, mean reduction in BMI from baseline to month 12 was 3.4 ± 0.7% (P < 0.01). Use of MR significantly improved short-term weight loss, compared with CD, but its continued use did not improve maintenance of lost weight. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text